Goldman Sachs Removes ISRG from Americas Sell List

Goldman Sachs has issued a report that Intuitive Surgical ISRG has been removed from Americas Sell List and upgraded to a Neutral Rating. Goldman Sachs writes, "Following strong 2Q2011 results, evidence has emerged that the company has more potential longterm growth drivers (namely new procedure categories and the ability to reach a broader hospital population) than we had factored into our thesis." ISRG has a $370 Price Target and closed yesterday at $374.90 a share.